Core Insights - Prenetics Global Limited will participate in the 38th Annual ROTH Conference from March 22nd to March 24th, 2026 [1] - CEO Danny Yeung and President of Americas David Vanderveen will hold one-on-one meetings and participate in a fireside chat and a Consumer Influencer panel discussion during the conference [2] - IM8, Prenetics' flagship brand, has surpassed $100 million in annualized recurring revenue within 11 months of operations and is sold in over 30 countries [4] Company Overview - Prenetics is a leading health sciences company focused on advancing human health and longevity, with its premium brand IM8 co-founded by David Beckham [4] - IM8 combines cutting-edge science with natural ingredients to provide a holistic approach to health, featuring its flagship product, Daily Ultimate Essentials, which replaces 16 different supplements [5] - IM8 is NSF Certified for Sport, non-GMO, vegan, and free from common allergens, artificial flavors, colors, or sweeteners [5]

Core Insights - Prenetics Global Limited has launched Daily Ultimate Essentials PRO, a clinical-grade version of its flagship health supplement, featuring enhanced potency and new flavors while maintaining the same price for customers [1][2][5]. Product Launch - The new PRO formula includes significant increases in key nutrients, such as Vitamin B12 (up 733% to 200mcg) and Cell Renewal (up 300% to 100mg), aimed at delivering clinical-grade nutritional impact [3]. - Two new flavors, Mango + Passionfruit and Lemon + Orange, have been introduced to cater to consumer demand for variety [1][4]. Customer Engagement - Daily Ultimate Essentials has received over 10,000 five-star reviews and achieved more than 670,000 customer purchases since its launch, indicating strong market acceptance [2]. - Existing subscribers will be automatically upgraded to the PRO formula at no additional cost, ensuring accessibility for all customers [5]. Nutritional Advancements - The PRO formula features bioactive forms of Vitamin B6 and Riboflavin, enhancing nutrient absorption and utilization [3]. - The addition of saffron extract as a new ingredient aims to support mood and cognitive clarity [3]. Company Overview - Prenetics is a leading health sciences company focused on advancing human health and longevity, with its flagship brand IM8 co-founded by David Beckham [6][7]. - IM8 has rapidly grown, surpassing $100 million in annualized recurring revenue within 11 months and is now available in over 30 countries [6].

Core Insights - Prenetics Global Limited has appointed Dr. Darshan Shah as an independent director to its Board of Directors, effective February 16, 2026, enhancing the Board's clinical and commercial expertise in healthspan optimization [1][3] Clinical and Longevity Expertise - Dr. Shah is a board-certified surgeon with over 20 years of experience in clinical practice and healthcare entrepreneurship, having performed over 20,000 surgical procedures [2][4] - His recent focus has been on longevity and healthspan optimization, advising thousands of patients on data-driven wellness protocols, which provides critical technical oversight for Prenetics [5] Health Sciences Entrepreneurship - Dr. Shah is the Founder and CEO of Next Health, a leading health optimization and longevity center, which is set to expand to over 30 locations by the end of 2026 under his leadership [6] Academic and Professional Affiliations - Dr. Shah hosts the EXTEND Podcast, engaging with leading scientists on health advancements, and is an alumnus of Harvard Business School and Singularity University [7] About Prenetics - Prenetics is a leading health sciences company focused on advancing human health and longevity, with its flagship brand IM8 achieving over $100 million in annualized recurring revenue within 11 months of operations and sold in more than 30 countries [8][9]

Core Insights - Prenetics Global Limited has completed the sale of its 35% equity interest in Insighta to Tencent for $70 million, marking a significant milestone in its strategic transformation to focus on the IM8 brand [1][7][9] Financial Position - The transaction provides an immediate increase in cash resources, enhancing the company's liquidity and financial flexibility, with $69 million received on February 13, 2026, and $1 million held in escrow [2][3] - As of February 15, 2026, Prenetics' total adjusted liquidity stands at $171.1 million, which includes cash and cash equivalents of $99.3 million and Bitcoin valued at $35.2 million [4][6] Strategic Focus - The sale is part of Prenetics' strategy to streamline operations and concentrate resources on IM8, which has become one of the fastest-growing brands in consumer health, achieving over $100 million in annualized recurring revenue within 11 months of operations [10][9] - The company operates with zero outstanding debt, positioning it to accelerate IM8's global expansion and invest in product innovation [6][9] Market Position - IM8, co-founded with David Beckham, is redefining the premium daily nutrition category through science-backed formulations and global partnerships, and is now sold in over 30 countries [10][11]

Core Insights - Prenetics Global Limited will release its financial results for Q4 and full year 2025 on February 18, 2026, before market open [1] - An earnings conference call will be held on the same day at 10:00 a.m. Eastern Time, including a Q&A session with analysts [1][2] Company Overview - Prenetics is a leading health sciences company focused on advancing human health and longevity, with its flagship brand IM8 co-founded by David Beckham [3] - IM8 has rapidly grown, surpassing $100 million in annualized revenue within 11 months and is now available in over 30 countries [3] - IM8's flagship product, Daily Ultimate Essentials, is designed to replace 16 different supplements and is NSF Certified for Sport, non-GMO, vegan, and free from common allergens [4]

Core Insights - Prenetics Global Limited has completed the sale of its 3PL distribution business, Europa Sports Partners, valued at up to $13 million, to focus on its IM8 brand [1][2][3] - The company maintains a strong balance sheet with over $70 million in cash and cash equivalents, 510 BTC, and zero debt, totaling approximately $118 million in liquidity [1][3] - The divestiture is part of Prenetics' strategic portfolio optimization, following the $72 million sale of ACT Genomics in October 2025, aimed at concentrating resources on the high-growth IM8 business [3][5] Financial Performance - The sale of the Europa business, completed on January 1, 2026, will not impact the company's revenue for fiscal year 2025, which will include the full-year contribution from Europa [4] - Prenetics projects total revenues from IM8 to be between $180 million and $200 million for the full year 2026 [3] - The divestiture is expected to improve operating margins starting Q2 2026, as the company will no longer incur approximately $6 million in operating losses from the Europa business [6] Strategic Focus - The sale allows Prenetics to sharpen its focus on IM8, which is rapidly scaling across international markets, aligning with the company's long-term logistics and global expansion requirements [2][5] - Prenetics plans to continue reviewing its remaining non-core assets, including a 35% stake in Insighta, valued at $70 million, to further simplify its business structure [7] - The company is optimistic about the future opportunities for IM8, which has achieved over $100 million in annual recurring revenue within 11 months of launch [8]

Core Insights - Prenetics Global Limited reported a significant increase in total revenue, surging 568% year-over-year to $23.6 million in Q3 2025, with a gross profit of $14.0 million, reflecting a 631.2% increase compared to Q3 2024 [14][25][9] - The company's IM8 brand achieved record monthly revenue of $9 million in October 2025, marking a 36% month-over-month growth from September [4][2] - IM8 is projected to reach $180 to $200 million in revenue for FY 2026, translating to approximately $25 million in monthly revenue or $300 million in annual recurring revenue (ARR) by the end of 2026 [21][11] Financial Performance - Q3 2025 financial highlights include a quarterly revenue of $23.6 million, a gross margin of 60%, and an adjusted EBITDA loss of $(2.1) million, improving from $(4.5) million in Q1 2025 [14][9][10] - The company reported a total of 420,000 customer purchases across 31 countries, with international markets contributing 56.5% of IM8's revenue [5][4] - The average order value for new customers increased to $150 in October 2025, up 36% from the previous month [6][8] Strategic Developments - Prenetics completed a $44 million equity offering in October 2025, attracting strategic investors, which positions the company for accelerated global expansion [3][10] - The company maintains a strong balance sheet with approximately $120 million in total liquidity and zero debt, allowing for aggressive scaling without dilutive capital needs [10][15] - Prenetics is executing a strategic review of non-core assets to focus on its highest-growth unit, IM8, following the successful divestiture of ACT Genomics [18][19] Market Positioning - IM8 is recognized for having the fastest growth trajectory in the global supplements industry, achieving $108 million in ARR within 11 months of launch [25][2] - The company is also pioneering a dual-engine strategy by integrating Bitcoin as a strategic treasury asset, currently holding 387 BTC valued at approximately $41 million [16][26] - Prenetics aims to replicate the success of direct-to-consumer brands like Hims & Hers, leveraging strong unit economics and a subscription-based revenue model [11][21]

Financial Performance - Company reported a revenue of $32.3 million for the first half of 2025, reflecting a year-over-year increase of 452.1% compared to the first half of 2024 [1][5] - In the second quarter of 2025, revenue reached $17.7 million, an increase of 594.9% compared to the second quarter of 2024 [5][30] - Gross profit for the first half of 2025 was $13.2 million, up 166.4% from the same period in 2024 [5] - Adjusted EBITDA loss for the first half of 2025 was $(8.7) million, which is an increase of 45.4% compared to the first half of 2024 [5] Business Unit Performance - IM8 generated $15.5 million in revenue for the first half of 2025, with a monthly revenue of $5.9 million in August 2025, indicating a CAGR of over 3,100% [6][12] - Europa and CircleDNA contributed $12.0 million and $4.8 million, respectively, to the first half revenue [13][36] - IM8's revenue in the second quarter was $9.8 million, a 70% increase over the first quarter of 2025 [5] Strategic Initiatives - Company has initiated a disciplined Bitcoin treasury strategy, acquiring a total of 228 Bitcoin as of September 10, 2025, with an unrealized gain of approximately $1.6 million [15][16] - Prenetics aims to achieve break-even by Q1 2026 and has increased its full-year 2025 revenue guidance to a range of $85 - $100 million [17][18] Market Position and Brand Development - IM8 has rapidly emerged as one of the fastest-growing supplement brands globally, with over 8 million servings delivered and more than 300,000 customer orders [10][12] - The brand's marketing efforts, including a partnership with Aryna Sabalenka, have significantly enhanced its visibility, generating 233 million views during the US Open [10][11] Financial Health - As of September 10, 2025, the company held $90 million in cash and Bitcoin, remaining debt-free [2][5] - Adjusted current assets were reported at $90.3 million, including $63.5 million in cash [5][38]

Core Insights - Prenetics Global Limited reported a significant revenue growth of 452.1% year-over-year, reaching $32.3 million in the first half of 2025 [1][5] - The company achieved a remarkable monthly revenue of $5.9 million in August 2025 for its IM8 brand, with a compound annual growth rate (CAGR) exceeding 3,100% [1][12] - Prenetics has increased its full-year 2025 revenue guidance to a range of $85 million to $100 million and anticipates reaching break-even by Q1 2026 [1][17] Financial Performance - In Q2 2025, Prenetics generated $17.7 million in revenue, marking a 594.9% increase compared to Q2 2024 [5] - The gross profit for Q2 2025 was $7.3 million, up 233.5% from the same quarter in the previous year [5] - The adjusted EBITDA loss for Q2 2025 was $(4.1) million, a decrease of 8.7% compared to Q1 2025 [5] - The total loss for Q2 2025 was $(10.9) million, reflecting a 22.7% increase from Q2 2024 [5] Business Unit Performance - IM8 generated $9.8 million in revenue for Q2 2025, a 70% increase over Q1 2025 [5] - Europa and CircleDNA contributed $5.7 million and $2.2 million in revenue, respectively, for Q2 2025 [5] - For the first half of 2025, IM8's revenue was $15.5 million, while Europa and CircleDNA generated $12.0 million and $4.8 million, respectively [13] Strategic Initiatives - Prenetics has initiated a disciplined Bitcoin treasury strategy, acquiring a total of 228 Bitcoin, with a daily accumulation of 1 BTC starting August 2025 [1][15] - The company holds a strong cash position of $90 million, including $26.1 million in Bitcoin, and remains debt-free [2][5] - Prenetics aims to enhance shareholder value through its strategic focus on both health and wealth optimization [2] Market Position and Growth Potential - IM8 has positioned itself as one of the fastest-growing supplement brands globally, with over 8 million servings delivered and more than 300,000 customer orders [12][10] - The brand's marketing efforts, including a partnership with Aryna Sabalenka, have significantly increased brand awareness, generating 233 million views during the US Open [10] - The company is optimistic about future product launches that will further solidify IM8's leadership in premium nutrition and longevity solutions [11]

Core Insights - Prenetics Global Limited announced a partnership between its premium supplements brand IM8 and world No. 1 tennis player Aryna Sabalenka, who becomes the brand's global ambassador and shareholder [1][6][12] - This partnership is significant as it marks the first endorsement of a supplement brand by Sabalenka, who has reported substantial benefits from using IM8's Daily Ultimate Essentials [3][4][5] Company Overview - Prenetics is a leading consumer health sciences company listed on NASDAQ under the ticker PRE, focusing on advancing consumer health through various initiatives, including IM8 [10] - IM8, co-founded by David Beckham, has rapidly grown to generate over US$50 million in Annual Recurring Revenue within just six months of its launch [6][8] - IM8 has built a loyal customer base of over 60,000 users, delivering more than 5 million servings of its products [6][8] Product Details - IM8's flagship product, Daily Ultimate Essentials, is designed to replace 16 different supplements with a single, NSF Certified for Sport® powder supplement [11] - The product is non-GMO, vegan, free from common allergens, and contains no artificial flavors, colors, or sweeteners [11] Market Context - The partnership comes at a time when supplement safety and quality are critical issues in professional sports, with IM8's NSF Certified for Sport® designation ensuring rigorous testing for prohibited substances [7] - IM8's revenue growth trajectory exceeds typical benchmarks for successful supplement launches by 500%, indicating strong market demand and acceptance [8]